Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco.
Special Advisory:
Job applicants should be aware of online recruitment scams, including fraudulent interviews and fake job offers. Akero does not conduct interviews through text messages or messaging apps, will never request money from applicants, and communicates only via emails ending with "@akerotx.com." Please verify that any communication claiming to be from Akero comes from an official company email address. If you receive any suspicious messages, submit a report to the Federal Trade Commission.
Company Details
- Employees
- 69
- Founded
- -
- Address
- 601 Gateway Blvd,
- in****@****otx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- akerotx.com
- HQ
- South San Francisco, California
Akero Therapeutics Questions
Akero Therapeutics's website is akerotx.com
Akero Therapeutics's LinkedIn profile is https://www.linkedin.com/company/akerotx
Akero Therapeutics has
69 employees.
View email and phone details for 69
employees at Akero Therapeutics.
Akero Therapeutics's industry is
Biotechnology Research
Akero Therapeutics's top competitors are
Atalanta Therapeutics,
Helicore Biopharma,
89bio,
Abcuro, Inc,
Disc Medicine,
Viking Therapeutics, Inc.,
Madrigal Pharmaceuticals,
Vertex Pharmaceuticals,
Vera Therapeutics, Inc.,
Terns Pharmaceuticals.
Akero Therapeutics's support email address is info@akerotx.com
Akero Therapeutics's categories are Biotechnology Research
Akero Therapeutics's founding year is 2017
